Liquid biopsy — the analysis of circulating tumor DNA, circulating tumor cells, exosomes, and other cancer-derived materials in blood to detect, characterize, and monitor cancer non-invasively — represents a transformative precision oncology diagnostic approach, with the Precision Medicine Market reflecting liquid biopsy as one of the most commercially significant precision medicine market segments.

Guardant360 CDx and FoundationOne Liquid CDx — the FDA-approved comprehensive liquid biopsy platforms detecting tumor mutations from plasma cell-free DNA for companion diagnostic purposes and therapy selection — have established commercial liquid biopsy as a standard advanced cancer diagnostic tool. Guardant Health's revenue demonstrating the commercial liquid biopsy market scale and the clinical adoption of blood-based genomic profiling as an alternative or complement to tissue biopsy for actionable mutation identification.

Grail Galleri multi-cancer early detection — the cell-free DNA methylation-based blood test detecting fifty-plus cancer types from a single blood draw — represents the liquid biopsy application extending beyond therapy selection into cancer screening. Grail's multi-cancer early detection test performing in real-world health systems through the NHS Galleri trial and US commercial launch represents the potentially most impactful cancer detection innovation in decades if prospective outcome studies confirm clinical benefit.

ctDNA minimal residual disease monitoring — the application of ultra-sensitive cfDNA sequencing to detect residual cancer after curative-intent treatment months before radiographic recurrence — enables treatment strategy modification based on molecular recurrence signals. Signatera (Natera), Personalis NeXT Liquid Biopsy, and Foundation Medicine ctDNA MRD monitoring tests are progressing toward clinical guideline inclusion in colorectal, breast, and lung cancer surveillance with growing evidence for MRD-guided treatment decisions.

Do you think multi-cancer early detection tests will be incorporated into routine cancer screening programs within five years, or will the evidence development and healthcare system implementation challenges require longer timelines?

FAQ

What is ctDNA and how is it used in oncology? Circulating tumor DNA (ctDNA) is fragmented DNA released by tumor cells into the bloodstream; ctDNA carries tumor-specific mutations detectable by highly sensitive sequencing techniques; ctDNA applications include: therapy selection from detectable actionable mutations, treatment monitoring from ctDNA clearance or emergence of resistance mutations, minimal residual disease detection after surgery, and cancer screening (Galleri); ctDNA fraction in plasma ranges from less than one percent in early cancer to tens of percent in late-stage disease, requiring ultra-sensitive detection methods.

What is the Galleri multi-cancer detection test? Galleri (Grail) uses cell-free DNA methylation patterns analyzed by machine learning to simultaneously screen for over fifty cancer types and predict tissue of origin; methylation patterns differ between cancer-derived and normal DNA enabling cancer signal detection; sensitivity varies by cancer type (highest for late-stage, lower for early-stage); overall sensitivity approximately fifty percent with high specificity (false positive rate less than one percent); the NHS-Galleri trial in the UK is evaluating clinical benefit in real-world screening; commercially available in the US for adults forty-five and older as a supplemental screening test.

#PrecisionMedicine #LiquidBiopsy #ctDNAliquidBiopsy #Guardant360 #GalleriCancer Screening #MRDmonitoring